Article
HER2 alterations across solid tumors: implications for comprehensive testing
16 Aug 2025
Abstract excerpt
PURPOSE: ERBB2 (HER2) alterations (eg, overexpression, amplification, and mutations) are known to drive tumor progression. These changes, particularly in non-breast and gastric/gastroesophageal cancers, remain poorly characterized. With pan-tumor approval of HER2-targeted therapies like Trastuzumab deruxetecan (T-DXd), understanding ERBB2 alterations across diverse cancers is crucial. METHODS: HER2 analysis was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
